Shares of Cardlytics (CDLX) are moving higher after Andrew Left’s Citron Research, best known for its short selling reports, listed the top reasons to buy the stock. ” Citron pounds the table and now is the time to look at $CDLX as the wind is finally at their back,” the firm said in a report on its website. Cardlytics shares are up 22%, or 46c, to $2.55 in afternoon trading. The firm sees $10 per share as a “reasonable” price target “that can happen with just one” customer announcement. Signing up a major publisher on Cardlytics’ rewards platform “changes this company overnight, and helps the consumer,” Citron contends.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDLX:
- Cardlytics benefits from Wells Fargo push into cards, Citron says
- Largest borrow rate increases among liquid names
- Cardlytics, Inc. Balances Growth and Challenges in Earnings Call
- Cardlytics: Balancing Growth with Uncertainty – Hold Rating Amidst Partnership and Stability Concerns
- Cardlytics Reports Q2 2025 Financial Results